We also validated that patients with high ALKBH5 or FTO expression had significantly shorter overall survival compared with those with low expression in Mulligan et al. [32] myeloma cohort (GSE9782) (Figs. 1H and S1F). This evidence concerns the gene ALKBH5 and plasma cell myeloma.